Polypharmacy in Cancer Therapy

Cavalcanti, Iago Dillion Lima

doi:10.1007/978-3-031-10839-6_1

Cited by 2 publications

(1 citation statement)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hazard factors for polypharmacy in patients with cancer are the number of health problems, inpatient admissions, and prescriptions to manage adverse drug reactions with adjunctive medications. The repercussions of polypharmacy in oncology are adverse drug reactions, DDIs, incremental hazards of morbidity, and mortality [105][106][107].…”

Section: Qt Interval Extending Ddis With Anticancer Agentsmentioning

confidence: 99%

Prevalence, Attributes, and Risk Factors of QT-Interval-Prolonging Drugs and Potential Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital

Agnihotri,

Ramasubbu,

Bandyopadhyay

et al. 2024

Cureus

View full text Add to dashboard Cite

Introduction Cancer chemotherapy regimens include multiple classes of adjuvant drugs as supportive therapy. Because of the concurrent intake of other drugs (like antiemetics, antidepressants, analgesics, and antimicrobials), there is a heightened risk for possible QT interval prolongation. There is a dearth of evidence in the literature regarding the usage of QT-prolonging anticancer drugs and associated risk factors that have the propensity to prolong QT interval. The purpose was to explore the extent of the use of QT-interval-prolonging drugs and potential QT-prolonging drug-drug interactions (QT-DDIs) in cancer patients attending OPD in a tertiary-care hospital. Methods This was a hospital-based, cross-sectional, observational study. Risk stratification of QT-prolonging drugs for torsades de pointes (TdP) was done by the Arizona Center for Education and Research on Therapeutics (AzCERT)/CredibleMeds-lists, and potential QT-DDIs were determined with four online DDI-checker-software. Results In 1331 cancer patients, the overall prevalence of potential QT-prolonging drug utilization was 97.3%. Ondansetron, pantoprazole, domperidone, and olanzapine were the most frequent QT-prolonging drugs in cancer patients. The top six antineoplastics with potential QT-prolonging and torsadogenic actions were capecitabine, oxaliplatin, imatinib, bortezomib, 5-fluorouracil, and bendamustine. Evidence-based pragmatic QTc interval prolongation risk assessment tools are imperative for cancer patients. Conclusion This study revealed a high prevalence of QT-prolonging drugs and QT-DDIs among cancer patients who are treated with anticancer and non-anticancer drugs. As a result, it's critical to take precautions, stay vigilant, and avoid QT-prolonging in clinical situations. Evidence-based pragmatic QTc interval prolongation risk assessment tools are needed for cancer patients.

show abstract

Section: Qt Interval Extending Ddis With Anticancer Agentsmentioning

confidence: 99%

Prevalence, Attributes, and Risk Factors of QT-Interval-Prolonging Drugs and Potential Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital

Agnihotri,

Ramasubbu,

Bandyopadhyay

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

Role of the Pharmacist in the Management of Polypharmacy and Drug Interactions in the Elderly Patient with Chemotherapy

Cavalcanti

Souza²,

Soares

2024

CCTR

View full text Add to dashboard Cite

Methods: An narrative literature review was carried out using the descriptors "Polypharmacy", "Pharmacological interactions", "Geriatrics" and "Antineoplastic agents", in the ScienceDirect, MEDLINE, and CAPLUS databases. Results: One hundred and ten articles were identified, of which 82 were included in this review. The articles showed the importance of evaluating drug interactions in the treatment of cancer in oncogeriatric patients due to the high amount of drugs that these patients use, which can exceed 6 drugs per day, and that these interactions can compromise the treatment of the patient, as well as induce serious toxic effects, causing the patient to be hospitalized or even die. Conclusion: The inclusion of the pharmacist in the care of oncogeriatric patients reduces the risk of interaction through pharmacotherapeutic monitoring.

show abstract

Polypharmacy in Cancer Therapy

Cited by 2 publications

References 137 publications

Prevalence, Attributes, and Risk Factors of QT-Interval-Prolonging Drugs and Potential Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital

Prevalence, Attributes, and Risk Factors of QT-Interval-Prolonging Drugs and Potential Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital

Role of the Pharmacist in the Management of Polypharmacy and Drug Interactions in the Elderly Patient with Chemotherapy

Contact Info

Product

Resources

About